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Background:  The coronary slow flow (CSF) phenomenon is a delayed antegrade progression of contrast agent to the distal branch of a 
coronary artery in the absence of obstructive coronary artery disease (CAD). Levels of visfatin, a novel adipocytokine, are reported to be 
increased in atherosclerosis, obesity, and type 2 diabetes. The aim of the present study was to investigate the relation between CSF and 
visfatin in patients who underwent elective coronary angiography (CAG) for stable angina pectoris (SAP).
methods:  Elective CAG procedure was performed on the 1352 consecutive patients between May 2013 and July 2014 with an initial 
diagnosis of SAP. Ninety patients (6.6%) who had angiographically proven normal coronary arteries and CSF were included in the 
study. During study period, of the 182 patients (13%) who had normal coronary arteries and normal coronary flow, 50 patients were 
randomly selected as the control group by three experienced cardiologists, who were independent from the study. Coronary flow was 
quantified by thrombolysis in myocardial infarction (TIMI) frame count (TFC). Serum visfatin levels were measured with an enzyme-linked 
immunosorbent assay method.
results:  Serum visfatin levels were higher in the CSF group compared with the controls (3.29 ± 1.11 vs. 2.26 ± 0.42 ng/mL, p < 0.001). 
In addition, those with CSF involving all three vessels had significantly higher visfatin levels than those with two-vessel or one-vessel 
CSF (3.99±1.93 vs. 3.39±0.89 vs. 2.96±0.64 ng/mL). A significant correlation was found between TFC and visfatin (r = 0.535, p < 0.001). 
The area under the receiver operating characteristic curve was 0.879 (95% confidence interval, 0.814 - 0.928, p = 0.028) for visfatin in 
the diagnosis of CSF. If a value of 2.55 ng/mL was used as cutoff, higher levels of visfatin could predict the presence of CSF with 83.0% 
sensitivity and 86.0% specificity.
Conclusion:  This is the first study to demonstrate the significant association between increased serum visfatin levels and the presence 
and extent of CSF. We conclude that visfatin levels might be a useful biomarker for predicting CSF in patients who undergo elective 
coronary angiography for stable angina pectoris.
